JPRN-jRCTs031180043
Completed
Phase 4
Investigation of the effect of empagliflozin on cardiac sympathetic and parasympathetic nerve activity in Japanese patients with type 2 diabetes (EMPYREAN) - EMPYREA
Kuwahara Kouichiro0 sites113 target enrollmentNovember 27, 2018
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kuwahara Kouichiro
- Enrollment
- 113
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Effects of empagliflozin and sitagliptin on autonomic nerve activities were not significantly different in patients with type 2 DM.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Type 2 DM (HbA1c 6\.5\-10%) . HbA1c 7\.0\-10% for patients who are taking sulfonylurea/glinides.
Exclusion Criteria
- •Treated with Insulin, GLP\-1 analogue, SGLT2/DPP4 inhibitors
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
A study examining the effects of empagliflozin (Jardiance®), a tablet for treatment of diabetes on autonomic nervous system and heart function in patients with type 2 diabetes.Type 2 DiabetesMetabolic and Endocrine - DiabetesCardiovascular - Normal development and function of the cardiovascular systemACTRN12619000887178Baker Heart and Diabetes Institute60
Not yet recruiting
Phase 2
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
Not yet recruiting
Phase 2
Assessment of extra-renal effects of SGLT2-inhibitors in anuric haemodialysis patients using microneurographyACTRN12623001237673Dobney Hypertension Centre20
Completed
Not Applicable
Investigation of the effect of empagliflozin on cardiac sympathetic and parasympathetic nerve activity in Japanese patients with type 2 diabetesDiabetes Mellitus (type 2)JPRN-UMIN000029194Shinshu University School of Medicine112
Completed
Phase 3
Effects of empagliflozin in diabetes treatmentIRCT20191126045505N1Bojnourd University of Medical Sciences100